A-CAR032

A-CAR032 is a code name for an investigational drug, likely a chimeric antigen receptor T cell (CAR-T) therapy. CAR-T therapies are advanced immunotherapies in which a patient's T cells are genetically engineered to express chimeric antigen receptors that target specific antigens on tumor cells. These modified T cells can recognize and kill cancer cells independently of MHC presentation, combining the specificity of monoclonal antibodies with the cytolytic capacity of T cells. The mechanism involves binding to tumor-associated antigens via the CAR's single-chain variable fragment (scFv), leading to activation, cytokine release, and direct cytotoxicity against cancer cells[6][8]. Specific details about the targeted antigen or clinical indications for A-CAR032 are not available in public sources as of April 2025[1].

Other names

dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell InjectionSTEAP2-targeted CAR T-cell therapySTEAP-2-targeted CAR T-cell therapySTEAP 2-targeted CAR T-cell therapy